Our reagent cost comparison shows that targeted NGS is a cost-effective alternative to Sanger sequencing for complex diseases requiring >60 amplicons (e.g., DOCK8 deficiency) and for diseases associated multiple candidate genes (e.g., ALPS, SCID, HIGM, and MSMD). The gene discussed is DOCK8; the disease is hyperinsulinemic hypoglycemia, familial, 4.